Human Factor IX (Factor 9) ELISA Kit

A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum

• https://www.nature.com/articles/s41467-018-04221-9
• A Roth, SP Maher, AJ Conway, R Ubalee… - Nature …, 2018 - nature.com
• Malaria liver stages represent an ideal therapeutic target with a bottleneck in parasite load and reduced clinical symptoms; however, current in vitro pre-erythrocytic (PE) models for …

* Than PA et al. (2022) Selective Microvascular Tissue Transfection Using Minicircle DNA for Systemic Delivery of Human Coagulation Factor IX in a Rat Model Using a Therapeutic Flap. Plast Reconstr Surg. 149(1):117-129

• https://pubmed.ncbi.nlm.nih.gov/34757962/#affiliation-1

* Kruse RL (2021) Endoscopic-mediated, biliary hydrodynamic injection mediating clinically relevant levels of gene delivery in pig liver. Gastrointest Endosc. S0016-5107(21)01463-2.

• https://pubmed.ncbi.nlm.nih.gov/34197834/#affiliation-1

* Engelmann B (2018) Plasma Proteome Analyses of Experimental Human and Murine Thyroid Disease Models. Ernst Moritz Arndt University of Greifswald. Dessertation.

• https://epub.ub.uni-greifswald.de/frontdoor/deliver/index/docId/2118/file/Dissertation_Beatrice_Engelmann.pdf

* Ramaswamya S et al. (2017) Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci USA. 114(10):E1941-E1950.

• https://www.pnas.org/doi/pdf/10.1073/pnas.1619653114

* DeRosa F et al. (2016) Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Therapy 23:699-

• http://www.nature.com/gt/journal/v23/n10/full/gt201646a.html

* Heartlein M et al. (2015) Lipid formulations for delivery of messenger rna. Patents: US 20150140070 A1.

• http://www.google.com.pr/patents/US20150140070

* Maher SP (2014) Development of an efficient human hepatocyte culture platform for assessing novel therapeutic efficacy against Plasmodium liver parasites. University of South Florida. Graduate Theses and Dissertations.

• https://digitalcommons.usf.edu/cgi/viewcontent.cgi?article=6459&context=etd

* Heartlein M (2014) Mrna therapeutic compositions and use to treat diseases and disorders. Patent application:WO2014152940 A1

• http://www.google.com/patents/WO2014152940A1?cl=en

* Derosa F et al.(2014) Lipidic nanoparticles for mrna delivering. Patent application:WO2014089486 A1

• http://www.google.com/patents/WO2014089486A1?cl=en

* Ostroff RM et al. (2012) Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One. 7(10):e46091

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463527/pdf/pone.0046091.pdf

* Guild BC et al. (2012) Lipid nanoparticle compositions and methods for mrna delivery. Patent Application WO2012170930 A1

• http://www.google.com/patents/WO2012170930A1?cl=en

* Fima UE et al. (2010) Long-Acting Coagulation Factors and Methods of Producing Same. Patent No: US 8476234 B2

• http://www.freepatentsonline.com/8759292.html

* Dadehbeigi N et al. (2008) Sex hormones affect the production of recombinant Factor IX in CHO and HEK-293 cell lines. Biotechnol Lett. 30(11):1909-12

• https://pubmed.ncbi.nlm.nih.gov/18581062/#affiliation-1